Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies

Purpose: IgM monoclonal gammopathy of undetermined sig-nificance (MGUS) and Waldenstro euro m macroglobulinemia (WM) represent a disease spectrum with highly varied therapeutic man-agement, ranging from observation to chemoimmunotherapy. The current classification relies solely on clinical features and does not explain the heterogeneity that exists within each of these conditions. Further investigation is warranted to shed light on the biology that may account for the clinical differences.Experimental Design: We used bone marrow (BM) clonal CD19+ and/or CD138+ sorted cells, matched BM supernatant, and peripheral blood serum from 32 patients (7 MGUS, 25 WM) to perform the first multi-omics approach including whole-exome sequencing, RNA sequencing, proteomics, metabolomics, and mass cytometry.Results: We identified three clusters with distinct pathway activation, immune content, metabolomic, and clinical features.Cluster 1 included only patients with WM and was characterized by transcriptional silencing of genes involved in cell cycle and immune response, enrichment of mitochondrial metabolism, infiltration of senescent T effector memory cells, and aggressive clinical behavior. Genetic/structural alterations of TNFAIP3 were distinct events of this cluster. Cluster 2 comprised both MGUS and WM patients with upregulation of inflammatory response, senescence and glycolysis signatures, increased acti-vated T follicular helper and T regulatory cells, and indolent clinical behavior. Cluster 3 also included both MGUS and WM patients and exhibited intermediate features, including pro-liferative and inflammatory signaling, as well as glycolysis and mitochondrial metabolism.Conclusions: We have identified three distinct molecular clus-ters, suggesting a potential biologic classification that may have therapeutic implications.